Home »
Until now, patients with heart failure with preserved ejection fraction—the most common type of heart failure in the elderly—have had no access to evidenced-based treatments. For the first time, a large clinical trial led by
No one expects to leave their doctor’s appointment sicker than when they walked in. Yet new research from the University of Minnesota School of Public Health, Harvard University and athenahealth, Inc. provides new evidence about
Currently, patients with HFpEF have high risk of morbidity and mortality, but there is no effective measure for evaluating the prognosis. Studies have found that a variety of pathways can lead to the development of
Coronavirus vaccines ARE effective in cancer patients: More than 85% developed antibodies after a second dose of Pfizer, study finds After two doses of Pfizer’s COVID-19 vaccine, cancer patients are likely to be protected against
Older patients should be assessed for cognitive function and frailty on admission to hospital to improve rehabilitation programs and discharge planning, according to the research published by the Medical Journal of Australia. Researchers from the
Heart failure patients aged 80 and above are less likely to receive recommended therapies and dosages compared to their younger counterparts, according to research presented today at Heart Failure 2021, an online scientific congress of
A large cohort study found that despite impaired immunity, the vast majority of patients receiving dialysis maintained SARS-CoV-2 antibody levels 6 months after infection. A slow and continual decline in median antibody levels was observed
Early treatment with an asthma drug budesonide shortens recovery time in COVID-19 patients aged over 50 who are treated at home or in other community settings. The Platform Randomized Trial of Interventions against COVID-19 in
A McMaster University-led study has teased out the reason for blood clots caused by COVID-19, a serious potential complication of the virus. Blood from critically ill COVID-19 patients contains antibodies that can contribute to clotting,
Experimental drug cuts the risk of hospitalized COVID-19 patients needing a ventilator by 54%, trial data show Lenzilumab is a monoclonal antibody that targets a protein known as granulocyte-macrophage colony stimulating factor (GM-CSF) GM-CSF is